Tempus AI Inc. has announced the launch of its Fuses program, a groundbreaking initiative aimed at transforming therapeutic research and building the largest diagnostic platform using its novel foundation model. Utilizing a massive, multimodal dataset containing over 40 million research records, Tempus aims to enhance diagnostic, prognostic, and predictive modeling. The Fuses program will leverage this extensive dataset to develop AI-driven diagnostics that offer personalized care solutions, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. This initiative builds on Tempus' existing work, including the Immune Profile Score $(IPS)$ launched last year, and positions the company to deliver significant advancements in precision medicine. Eric Lefkofsky, Founder and CEO of Tempus, emphasized the potential for transformative change in matching therapies to patients, moving toward the realization of personalized care for millions.